Evidence map›Paper›PMID 9418900›Full record

ArticleMolecular and cellular biology1998

MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification.

O B Chernova, M V Chernov, Y Ishizaka, M L Agarwal, G R Stark

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. c-MYC-induced genomic instability.Cold Spring Harbor perspectives in medicine · 2014
    Review
  6. Article
  7. Article
  8. Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2008
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts.Proceedings of the National Academy of Sciences of the United States of America · 2000
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

O B ChernovaDepartment of Molecular Biology, Research Institute, The Cleveland Clinic Foundation, Ohio 44195, USA.
M V Chernov
Y Ishizaka
M L Agarwal
G R Stark
Cleveland Clinic · USSaitama International Medical Center · JP

Funding

P53 MODIFICATION AND NOVEL BIOLOGICAL FUNCTIONSR01GM049345 · NIGMS · CLEVELAND CLINIC LERNER COL/MED-CWRU · PI STARK, GEORGE ROBERT · 1993 to 2006
$2.5M
NIGMS NIH HHS R01 GM049345NIGMS NIH HHS R01 GM49345
6 · The paper itself

Abstract

Genomic instability, including the ability to undergo gene amplification, is a hallmark of neoplastic cells. Similar to normal cells, "nonpermissive" REF52 cells do not develop resistance to N-(phosphonacetyl)-L-aspartate (PALA), an inhibitor of the synthesis of pyrimidine nucleotides, through amplification of cad, the target gene, but instead undergo protective, long-term, p53-dependent cell cycle arrest. Expression of exogenous MYC prevents this arrest and allows REF52 cells to proceed to mitosis when pyrimidine nucleotides are limiting. This results in DNA breaks, leading to cell death and, rarely, to cad gene amplification and PALA resistance. Pretreatment of REF52 cells with a low concentration of PALA, which slows DNA replication but does not trigger cell cycle arrest, followed by exposure to a high, selective concentration of PALA, promotes the formation of PALA-resistant cells in which the physically linked cad and endogenous N-myc genes are coamplified. The activated expression of endogenous N-myc in these pretreated PALA-resistant cells allows them to bypass the p53-mediated arrest that is characteristic of untreated REF52 cells. Our data demonstrate that two distinct events are required to form PALA-resistant REF52 cells: amplification of cad, whose product overcomes the action of the drug, and increased expression of N-myc, whose product overcomes the PALA-induced cell cycle block. These paired events occur at a detectable frequency only when the genes are physically linked, as cad and N-myc are. In untreated REF52 cells overexpressing N-MYC, the level of p53 is significantly elevated but there is no induction of p21waf1 expression or growth arrest. However, after DNA is damaged, the activated p53 executes rapid apoptosis in these REF52/N-myc cells instead of the long-term protective arrest seen in REF52 cells. The predominantly cytoplasmic localization of stabilized p53 in REF52/N-myc cells suggests that cytoplasmic retention may help to inactivate the growth-suppressing function of p53.

Indexed as

Gene Expression Regulation, NeoplasticGenes, mycAnimalsAntineoplastic AgentsAspartate CarbamoyltransferaseAspartic AcidCarbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)Cell CycleDihydroorotaseDrug Resistance, NeoplasmMultienzyme ComplexesPhosphonoacetic AcidTumor Cells, CulturedTumor Suppressor Protein p53Antineoplastic AgentsAspartate CarbamoyltransferaseAspartic AcidCAD trifunctional enzymeCarbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)DihydroorotaseMultienzyme ComplexesPhosphonoacetic Acidsparfosic acidTumor Suppressor Protein p53

Identifiers

PMID9418900
PMCPMC121521
OpenAlexW1789331540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.